Dendright’s liposome-based therapy selectively turns off the immune response to the disease-specific antigen contained in that liposome. This enables us to target patients that will benefit most from treatment by selecting those patients that display an immune response (i.e. antibodies) towards the relevant antigen. Similarly, the patient’s response to therapy can be monitored via related immune biomarker assays.

It is our strategy to develop biomarkers that can be used in the clinical development of our liposome-based therapies.